Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Up 7.1% – Time to Buy?

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was up 7.1% during mid-day trading on Thursday . The company traded as high as $0.2447 and last traded at $0.2420. 536,395 shares traded hands during trading, an increase of 6% from the average daily volume of 503,976 shares. The stock had previously closed at $0.2260.

Theriva Biologics Price Performance

The company has a market capitalization of $8.17 million, a PE ratio of -0.01 and a beta of 1.14. The company has a quick ratio of 1.13, a current ratio of 1.13 and a debt-to-equity ratio of 0.13. The firm’s 50-day moving average is $0.23 and its 200-day moving average is $0.25.

Theriva Biologics (NYSEAMERICAN:TOVX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.07) earnings per share for the quarter.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.